James R. Overell

Glasgow, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis.

Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis.

Journal: EClinicalMedicine

Published: September 26, 2025

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: June 14, 2025

Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.

Cognitive effects of ocrelizumab vs interferon β-1a in relapsing multiple sclerosis: A post hoc analysis of the OPERA I/II trials.

Journal: Multiple sclerosis and related disorders

Published: August 24, 2024

Detecting fatigue in multiple sclerosis through automatic speech analysis.

Detecting fatigue in multiple sclerosis through automatic speech analysis.

Journal: Frontiers in human neuroscience

Published: June 14, 2024

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO).

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO).

Journal: Frontiers in neurology

Published: May 24, 2024

Brain reserve and physical disability in secondary progressive multiple sclerosis.

Brain reserve and physical disability in secondary progressive multiple sclerosis.

Journal: BMJ neurology open

Published: February 05, 2024

Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.

Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.

Journal: Multiple sclerosis and related disorders

Published: August 21, 2023

MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis.

MRI-derived g-ratio and lesion severity in newly diagnosed multiple sclerosis.

Journal: Brain communications

Published: March 27, 2021

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.

Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study.

Journal: The Lancet. Neurology

Published: January 12, 2021

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.

Journal: European journal of neurology

Published: December 03, 2020

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.

Journal: European journal of neurology

Published: December 03, 2020

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.

Journal: The Lancet. Neurology

Published: March 11, 2020

Showing 1-12 of 24

Last Updated: 09/26/2026